Advanced search
Publication Cover
Expert Opinion on Pharmacotherapy Volume 22, 2021 - Issue 8
Submit an article Journal homepage
5,994
Views
12
CrossRef citations to date
0
Altmetric
Drug Evaluation

Evaluating rimegepant for the treatment of migraine

Tessa de VriesErasmus MC, Department of Internal Medicine, Division of Pharmacology and Vascular Medicine, Rotterdam, NetherlandsView further author information
,
Linda Al-HassanyErasmus MC, Department of Internal Medicine, Division of Pharmacology and Vascular Medicine, Rotterdam, NetherlandsView further author information
&
Antoinette MaassenVanDenBrinkErasmus MC, Department of Internal Medicine, Division of Pharmacology and Vascular Medicine, Rotterdam, NetherlandsCorrespondence[email protected]
ORCID Iconhttps://orcid.org/0000-0001-7176-126XView further author information
ORCID Icon
Pages 973-979 | Received 16 Dec 2020, Accepted 23 Feb 2021, Published online: 10 Mar 2021

Citations (12)

Keep up to date with the latest research on this topic with citation updates for this article.

Subscribe to citation updates

Read on this site (3)

Cecilia Rustichelli, Rossella Avallone & Anna Ferrari. (2022) Atogepant: an emerging treatment for migraine. Expert Opinion on Pharmacotherapy 23:6, pages 653-662.
Read now
Sui-yi Xu, Hui-juan Li, Jing Huang, Xiu-ping Li & Chang-xin Li. (2021) Migraine with Brainstem Aura Accompanied by Disorders of Consciousness. Journal of Pain Research 14, pages 1119-1127.
Read now
Flavia Lo Castro, Simona Guerzoni & Lanfranco Pellesi. (2021) Safety and Risk of Medication Overuse Headache in Lasmiditan and Second-Generation Gepants: A Rapid Review. Drug, Healthcare and Patient Safety 13, pages 233-240.
Read now

Articles from other publishers (9)

Brenna L. Morse & Victoria Karian. (2023) Supporting the Young Adulthood Transitions in Women With Migraine. Nursing for Women's Health 27:6, pages 457-466.
Crossref
Rajinder Bhardwaj, Beth Morris, Richard Bertz, Robert Croop & Jing Liu. (2023) The Pharmacokinetics, Safety, and Tolerability of Rimegepant 75 mg Are Similar in Elderly and Nonelderly Adults: A Phase 1, Open‐Label, Parallel‐Group, Single‐Dose Study. Clinical Pharmacology in Drug Development.
Crossref
Rajinder Bhardwaj, Andrea Ivans, Joseph Stringfellow, Beth Morris, Vladimir Coric, Robert Croop & Richard Bertz. (2023) Rimegepant 75 mg in Subjects With Hepatic Impairment: Results of a Phase 1, Open‐Label, Single‐Dose, Parallel‐Group Study. Clinical Pharmacology in Drug Development 12:8, pages 790-800.
Crossref
Indu Passi, Sushant Salwan & Bhupinder Kumar. (2023) US-FDA Approved Drugs in 2020 and 2021: A Review. Mini-Reviews in Medicinal Chemistry 23:12, pages 1273-1297.
Crossref
Richard Bertz, Rajinder Bhardwaj, Beth A. Morris, Eric Ashbrenner, Vladimir Coric & Robert Croop. (2023) A placebo-controlled, randomized, single and multiple dose study to evaluate the safety, tolerability, and pharmacokinetics of rimegepant in healthy participants. Cephalalgia 43:6, pages 033310242311791.
Crossref
Shin T Zaw, Thinzar Zaw & Benito Torres. (2023) Use of Rimegepant in the Management of Cervicogenic Headache Secondary to Trauma: A Case Series. Cureus.
Crossref
Dilara Onan, William Wells-Gatnik & Paolo Martelletti. (2022) Reaching the Nadir of Medication Overuse in Chronic Migraine. International Journal of Environmental Research and Public Health 19:22, pages 14696.
Crossref
Rajinder Bhardwaj, Julie L. Collins, Joseph Stringfellow, Jennifer Madonia, Matt S. Anderson, Jeri‐anne Finley, David A. Stock, Vladimir Coric, Robert Croop & Richard Bertz. (2022) P‐Glycoprotein and Breast Cancer Resistance Protein Transporter Inhibition by Cyclosporine and Quinidine on the Pharmacokinetics of Oral Rimegepant in Healthy Subjects. Clinical Pharmacology in Drug Development 11:7, pages 889-897.
Crossref
Eduardo Rivera-Mancilla & Antoinette MaassenVanDenBrink. 2022. Novel Synthetic Drugs in Migraine. Novel Synthetic Drugs in Migraine 1 17 .

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.